Exelixis: the next-oncology-asset budget
Exelixis guides R&D expense to $825M–$875M, including specified stock compensation. The midpoint measures recorded investment rather than clinical success.
Exelixis / EXELPublic biotechR&D-spendingDate to watch
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
Primary evidence
Reporting date unconfirmed — research candidate
Exelixis Q3 2026 results and financial guidancePublished 2026-10-29
Potential outcome market
Will Exelixis 2026 GAAP R&D expense exceed $850 million?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.